Hepatitis Monthly

Published by: Kowsar

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1

Heidar Sharafi 1 , 2 , Seyed Moayed Alavian 1 , 2 and Maryam Keshvari 1 , 2 , 3 , *
Authors Information
1 Iran Hepatitis Network, Tehran, IR Iran
2 Middle East Liver Diseases Center (MELD), Tehran, IR Iran
3 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
Article information
  • Hepatitis Monthly: January 30, 2015, 15 (1); e24955
  • Published Online: January 1, 2015
  • Article Type: Research Article
  • Received: October 28, 2014
  • Revised: December 3, 2014
  • Accepted: December 31, 2014
  • DOI: 10.5812/hepatmon.24955

To Cite: Sharafi H, Alavian S M, Keshvari M. Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1, Hepat Mon. 2015 ;15(1):e24955. doi: 10.5812/hepatmon.24955.

Copyright: Copyright © 0, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2): 107-15[DOI][PubMed]
  • 2. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010; 8(2): 192-9[DOI][PubMed]
  • 3. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009; 96(9): 975-81[DOI][PubMed]
  • 4. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55(9): 1350-9[DOI][PubMed]
  • 5. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology. 2010; 51(2): 388-97[DOI][PubMed]
  • 6. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat. 2009; 16(10): 724-31[DOI][PubMed]
  • 7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 8. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5): 346-55[PubMed]
  • 9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65[PubMed]
  • 10. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011; 55(1): 69-75[DOI][PubMed]
  • 11. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008; 135(2): 451-8[DOI][PubMed]
  • 12. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60(2): 392-420[DOI][PubMed]
  • 13. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. Hepat Mon. 2012; 12(3): 190-5[DOI][PubMed]
  • 14. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006; 44(1): 97-103[DOI][PubMed]
  • 15. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43(5): 954-60[DOI][PubMed]
  • 16. Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, et al. Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study. Braz J Infect Dis. 2014; 18(1): 48-52[DOI][PubMed]
  • 17. Aghemo A, Degasperi E, Rumi MG, Galmozzi E, Valenti L, De Francesco R, et al. Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. Biomed Res Int. 2013; 2013: 580796[DOI][PubMed]
  • 18. Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, et al. Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol. 2014; 60(1): 16-21[DOI][PubMed]
  • 19. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis. 2008; 46(1): 78-84[DOI][PubMed]
  • 20. Sharafi H, Alavian SM. IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon. 2011; 11(12): 958-9[DOI][PubMed]
  • 21. Riva E, Scagnolari C, Monteleone K, Selvaggi C, Picardi A, Mazzarelli C, et al. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients. J Viral Hepat. 2012; 19(9): 650-3[DOI][PubMed]
  • 22. Chung HJ, Lee JW, Kim YS, Lee JI. Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area. Intervirology. 2013; 56(3): 178-83[DOI][PubMed]
  • 23. Corchado S, Lopez-Cortes LF, Rivero-Juarez A, Torres-Cornejo A, Rivero A, Marquez-Coello M, et al. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients. PLoS One. 2014; 9(7)[DOI][PubMed]
  • 24. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Salimi S, et al. Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals. Hepat Mon. 2012; 12(12)[DOI][PubMed]
  • 25. Sharafi H, Alavian SM, Behnava B, Pouryasin A, Keshvari M. The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon. 2014; 14(10)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader